natgillin/translations-raw huggingface dataset:
Trobalt has been compared with placebo (a dummy treatment) in three main studies involving a total of 1,244 patients whose seizures were not adequately controlled with other anti-epileptic medicines.
Zdravilo Trobalt so primerjali s placebom (zdravilom brez zdravilne učinkovine) v treh glavnih študijah, ki so vključevale skupno 1 244 bolnikov, pri katerih napadov ni bilo mogoče ustrezno nadzorovati z drugimi zdravili proti epilepsiji.
Lower doses should be used in older patients and in patients with moderate or severe liver or kidney problems.
Starejši bolniki in bolniki z zmernim ali hudim obolenjem jeter ali ledvic morajo uporabljati manjše odmerke.
Trobalt is used in combination with other anti-epileptic medicines to treat adults with drug-resistant partial-onset seizures (epileptic fits) that cannot be treated with other combinations of medicines.
Zdravilo Trobalt se uporablja v kombinaciji z drugimi zdravili proti epilepsiji za zdravljenje proti zdravilom odpornih konvulzij s parcialnim začetkom (epileptičnih napadov) pri odraslih, ki jih ni mogoče zdraviti z drugimi kombinacijami zdravil.
Trobalt must not be used in people who are hypersensitive (allergic) to retigabine or any of the other ingredients.
Zdravila Trobalt ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) retigabin ali katero koli drugo sestavino zdravila.
Trobalt has an effect on the potassium channels located on the nerve cells of the brain.
Zdravilo Trobalt vpliva na kalijeve kanale, ki se nahajajo na živčnih celicah v možganih.
Why has Trobalt been approved?
Zakaj je bilo zdravilo Trobalt odobreno?
For the full list of all side effects reported with Trobalt, see the package leaflet.
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Trobalt, glejte navodilo za uporabo.
Trobalt is a medicine that contains the active substance retigabine.
Trobalt je zdravilo, ki vsebuje zdravilno učinkovino retigabin.
The most common side effects with Trobalt (seen in more than 1 patient in 10) are dizziness, somnolence (sleepiness), fatigue (tiredness) as well as pigment changes (discolouration) of parts of the eye (including the retina, the light sensitive membrane at the back of the eye) and discolouration of the nails, lips and skin, which have been reported after several years of treatment.
Najpogostejši neželeni učinki zdravila Trobalt (opaženi pri več kot 1 bolniku izmed 10) so omotica, zaspanost, utrujenost ter pigmentne spremembe (sprememba barve) delov oči (vključno z mrežnico, na svetlobo občutljivo membrano v ozadju očesa) in sprememba barve nohtov, ustnic in kože, o čemer so poročali po večletnem zdravljenju.
It will also include information on some less common side effects that have been reported with the medicine, such as problems with passing urine, prolonged QT interval (an alteration of the electrical activity of the heart) and hallucinations (seeing or hearing things that are not there).
Gradivo bo vsebovalo tudi informacije o nekaterih manj pogostih neželenih učinkih, o katerih so poročali pri uporabi zdravila, kot so na primer težave pri uriniranju, podaljšan interval QT (sprememba električne aktivnosti srca) ter halucinacije (prividi ali prisluhi).
Trobalt acts by keeping the potassium channels open.
Zdravilo Trobalt deluje tako, da ohranja kalijeve kanale odprte.
The active substance in Trobalt, retigabine, is an anti-epileptic medicine.
Zdravilna učinkovina zdravila Trobalt, retigabin, je zdravilo za zdravljenje epilepsije.
In the first study, Trobalt at 900 mg a day and 1,200 mg a day was more effective than placebo and reduced the number of seizures per month by 29% and 35% respectively.
V prvi študiji je bilo jemanje 900 mg in 1 200 mg zdravila Trobalt na dan učinkovitejše od placeba in je število mesečnih napadov zmanjšalo za 29 % oziroma 35 %.
The CHMP noted that Trobalt is effective at reducing the number of seizures.
Menil je, da je zdravilo Trobalt učinkovito pri zmanjševanju števila napadov.
Trobalt at a maintenance dose of 600, 900 or 1,200 mg a day or placebo was taken for 8 weeks in the first study and 12 weeks in the other two studies.
V prvi študiji so bolniki prejemali 600-, 900- ali 1 200-miligramski vzdrževalni odmerek zdravila Trobalt na dan ali placebo osem tednov, v drugih dveh študijah pa 12 tednov.
In the second study, seizures were at least halved in 39% (61 out of 158 patients) of the patients on 600 mg Trobalt a day and in 47% (70 out of 149 patients) of the patients on 900 mg a day, compared with 19% (31 out of 164) of the patients on placebo.
V drugi študiji se je število napadov najmanj prepolovilo pri 39 % (61 od 158) bolnikov, ki so prejemali 600 mg zdravila Trobalt na dan, in 47 % (70 od 149) bolnikov, ki so prejemali 900 mg zdravila na dan, medtem ko je v skupini, ki je prejemala placebo, do tega prišlo pri 19 % (31 od 164) bolnikov.
This compared with a reduction of 13% in the placebo group.
V primerjavi s tem se je v skupini, ki je prejemala placebo, število mesečnih napadov zmanjšalo za 13 %.
In the third study, seizures were at least halved in 56% (66 out of 119 patients) of the patients taking 1,200 mg Trobalt a day, compared with 23% (31 out of 137) of the patients on placebo.
V tretji študiji se je število napadov najmanj prepolovilo pri 56 % (66 od 119) bolnikov, ki so jemali 1 200 mg zdravila Trobalt na dan, v skupini bolnikov, ki so prejemali placebo, pa pri 23 % (31 od 137) bolnikov.
What is Trobalt used for?
Za kaj se zdravilo Trobalt uporablja?
How has Trobalt been studied?
Kako je bilo zdravilo Trobalt raziskano?
What is Trobalt?
Kaj je zdravilo Trobalt?
How is Trobalt used?
Kako se zdravilo Trobalt uporablja?
How does Trobalt work?
Kako zdravilo Trobalt deluje?
The maximum dose is 25.2 g once a day.
Največji odmerek je 25,2 g enkrat na dan.
The recommended starting dose is 8.4 g once a day.
Priporočeni začetni odmerek je 8,4 g enkrat na dan.
What measures are being taken to ensure the safe and effective use of Veltassa?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Veltassa?
The full EPAR for Veltassa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Veltassa je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Hyperkalaemia can cause serious heart problems and muscle weakness.
Hiperkaliemija lahko povzroči hude težave s srcem in oslabelost mišic.
Other information about Veltassa
Druge informacije o zdravilu Veltassa
This is a summary of the European public assessment report (EPAR) for Veltassa.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Veltassa.
The European Medicines Agency decided that Veltassa's benefits are greater than its risks and recommended that it be approved for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila Veltassa večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
The side effects are relatively moderate but the doctor should take them into account when considering treatment with Veltassa.
Neželeni učinki so sorazmerno zmerni, vendar jih mora zdravnik ob načrtovanju zdravljenja z zdravilom Veltassa upoštevati.
The Veltassa mixture should be taken with food and at least 3 hours before or after any other medicines the patient takes by mouth.
Mešanico zdravila Veltassa je treba vzeti s hrano in vsaj tri ure pred jemanjem drugih peroralnih zdravil ali po tem.
Veltassa is available as sachets (8.4, 16.8 and 25.2 g) of patiromer containing a powder for mixing with water or some fruit juices and taking by mouth.
Zdravilo Veltassa je na voljo v obliki vrečic (8,4 g, 16,8 g in 25,2 g) patiromera, ki vsebujejo prašek, ki se zmeša z vodo ali nekaterimi sadnimi sokovi, in se zaužije peroralno.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Veltassa have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Veltassa upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
What are the risks associated with Veltassa?
Kakšna tveganja so povezana z zdravilom Veltassa?
What benefits of Veltassa have been shown in studies?
Kakšne koristi je zdravilo Veltassa izkazalo v študijah?
After 4 weeks of treatment, their potassium level fell on average by 1.0 mmol/litre.
Po štirih tednih zdravljenja se je njihova raven kalija povprečno znižala za 1,0 mmol/liter.
The most common side effects with Veltassa (which may affect more than 1 in 100 people) are those affecting the digestive system (constipation, diarrhoea, abdominal pain and wind) and blood tests showing low levels of magnesium in the blood.
Najpogostejši neželeni učinki zdravila Veltassa (ki se lahko pojavijo pri več kot 1 bolniku od 100) so učinki na prebavila (zaprtost, driska, bolečine v trebuhu in vetrovi) in rezultati krvnih preiskav, ki kažejo na nizko raven magnezija v krvi.
For more information about treatment with Veltassa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Veltassa preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What is Veltassa and what is it used for?
Kaj je zdravilo Veltassa in za kaj se uporablja?
patiromer draws potassium from the body into the gut and so reduces the amount of potassium in the blood.
Na ta način patiromer izloči kalij iz telesa v črevo ter zmanjša količino kalija v krvi.
Why is Veltassa approved?
Zakaj je bilo zdravilo Veltassa odobreno?
It is not intended to provide practical advice on how to use Veltassa.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
One main study involving patients with chronic kidney disease who had hyperkalaemia found that Veltassa is effective in reducing potassium levels in the blood.
V glavni študiji, ki je vključevala bolnike s kronično ledvično boleznijo, ki so imeli hiperkaliemijo, so ugotovili, da je zdravilo Veltassa učinkovito pri zniževanju ravni kalija v krvi.
After 4 weeks, the average potassium level did not change in patients who received Veltassa for 4 weeks but it went back up by an average of 0.7 mmol/litre in patients who received placebo.
Po štirih tednih se povprečna raven kalija pri bolnikih, ki so štiri tedne prejemali zdravilo Veltassa, ni spremenila, pri bolnikih, ki so prejemali placebo, pa se je dvignila za povprečno 0,7 mmol/liter.
For practical information about using Veltassa, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Veltassa naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
The second part of the study compared Veltassa with placebo (a dummy treatment) in 107 patients whose potassium level had fallen with Veltassa treatment during the first part of the study.
V drugem delu študije so primerjali zdravilo Veltassa s placebom (zdravilom brez zdravilne učinkovine) pri 107 bolnikih, pri katerih se je raven kalija med zdravljenjem z zdravilom Veltassa v prvem delu študije znižala.
When Veltassa is taken by mouth, the active substance, patiromer, remains in the gut where it attaches tightly to potassium to form a compound that is then passed out in the stool.
Ob peroralnem jemanju zdravila Veltassa zdravilna učinkovina patiromer ostane v črevesu, kjer se trdno veže na kalij in tvori spojino, ki se nato izloči z blatom.
In the first part of the study, 243 patients with hyperkalaemia (with average potassium level of 5.6 mmol/litre) were treated with Veltassa.
V prvem delu študije so z zdravilom Veltassa zdravili 243 bolnikov s hiperkaliemijo (s povprečnimi ravnmi kalija 5,6 mmol/liter).
Veltassa is a medicine used for treating adults with high levels of potassium in the blood (hyperkalaemia).
Zdravilo Veltassa se uporablja za zdravljenje visokih ravni kalija v krvi (hiperkaliemije) pri odraslih.
For the full list of all side effects and restrictions with Veltassa, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Veltassa glejte navodilo za uporabo.
The doctor then adjusts the dose at intervals of at least one week, based on the patient's blood levels of potassium.
Zdravnik nato enkrat tedensko prilagaja odmerek glede na raven kalija v bolnikovi krvi.
The Agency considered that there is a need for effective treatment of hyperkalaemia and Veltassa achieves a meaningful lowering of potassium levels.
Agencija je presodila, da obstaja potreba po učinkovitem zdravljenju hiperkaliemije, in z zdravilom Veltassa se ravni kalija pomembno znižajo.
Veltassa contains the active substance patiromer.
Zdravilo Veltassa vsebuje zdravilno učinkovino patiromer.
How does Veltassa work?
Kako zdravilo Veltassa deluje?
How is Veltassa used?
Kako se zdravilo Veltassa uporablja?
3 bottles
3 plastenke
Route of administration Immediate Packaging Content (concentration) Pack size
Stična ovojnina vsebina (koncentracija)
(Invented) name Strength
Številka (EU) dovoljenja za promet (Izmišljeno) ime Jakost
This overview was last updated in March 2019.
Povzetek je bil nazadnje posodobljen marca 2019.
This medicine is the same as NexGard, which is already authorised in the European Union (EU).
To zdravilo je enako zdravilu NexGard, ki je že odobreno v Evropski uniji (EU).
The blister with the remaining chewable tablets should be returned into the carton.
Pretisni omot s preostalimi žvečljivimi tabletami je treba vrniti v škatlo.
The appropriate strength of tablets to be given is determined based on the dog's bodyweight.
Ustrezna jakost tablete, ki jo je treba dati, se določi na podlagi telesne mase psa.
People handling the medicine should wash their hands after handling the product.
Osebe, ki rokujejo z zdravilom, si morajo po rokovanju z njim umiti roke.
In order for the active substance to have an effect, fleas and ticks must attach to the skin and start feeding on the dog's blood.
Da lahko učinkovina deluje, se morajo bolhe in klopi pritrditi na kožo in se začeti hraniti s krvjo psa.
Further information on Afoxolaner Merial can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/afoxolaner-merial.
Nadaljnje informacije o zdravilu Afoxolaner Merial so na voljo na spletni strani agencije: ema.europa.eu/medicines/veterinary/EPAR/felisecto-plus.
Afoxolaner Merial received a marketing authorisation valid throughout the EU on 20 May 2019.
Zdravilo Afoxolaner Merial je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 20. maja 2019.
This results in uncontrolled activity of the nervous system and the paralysis and death of fleas, ticks and mites.
S tem povzroči nenadzorovano delovanje živčnega sistema ter paralizo in smrt bolh, klopov in garjavcev.
The European Medicines Agency decided that Afoxolaner Merial's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je odločila, da so koristi zdravila Afoxolaner Merial večje od z njim povezanih tveganj, in da se lahko odobri za uporabo v EU.
Because parasites must start feeding on the dog in order to be killed by the medicine, there may be a risk of transmission of diseases with which they may be infected.
Ker se morajo zajedavci začeti hraniti s krvjo psa, da bi jih zdravilo lahko uničilo, ni mogoče izključiti tveganja za prenos bolezni, s katerimi so ti zajedavci lahko okuženi.
Only one chewable tablet at a time should be removed from the blister to prevent children from accessing the product.
Iz pretisnega omota odstranite le eno žvečljivo tableto naenkrat, da bi preprečili otrokom morebiten dostop do tega zdravila.
This means that it kills parasites that live on or in the skin or in the fur of animals, such as fleas, ticks and mites.
To pomeni, da uničuje zajedavce, ki živijo na koži ali v dlaki živali, kot so bolhe, klopi in garjavci.
Afoxolaner kills fleas before they can lay eggs and so helps to reduce contamination of the dogs' environment.
Afoksolaner ubije bolhe, preden izležejo jajčeca, s čimer pomaga zmanjšati kontaminacijo okolice psa.
Afoxolaner kills parasites by causing over-stimulation of their nervous system.
Afoksolaner zajedavce ubije tako, da pretirano stimulira njihov živčni sistem.
It may be used as part of the management of flea allergy dermatitis (an allergic reaction to flea bites).
Uporablja se lahko kot del zdravljenja alergijskega dermatitisa, ki ga povzročajo bolhe (alergijske reakcije na ugrize bolh).
Treatment should be repeated at monthly intervals during the flea or tick seasons, monthly for demodectic mange until the mange is successfully treated (as confirmed by two negative skin scrapings one month apart) and monthly for two months for sarcoptic mange, or longer if treatment is unsuccessful as indicated by clinical signs and skin scrapings.
Zdravljenje je treba ponavljati v mesečnih razmikih vso sezono bolh/klopov, enkrat mesečno pri garjavosti vrste Demodex canis, dokler ni uspešno pozdravljena (in potrjena z negativnimi rezultati dveh kožnih ostružkov, vzetih v enomesečnem razmiku), ter enkrat mesečno dva zaporedna meseca pri garjavosti vrste Sarcoptes scabiei oziroma dlje, če klinični znaki in ostružki kože nakazujejo, da zdravljenje ni bilo uspešno.
Afoxolaner Merial kills fleas within 8 hours and ticks within 48 hours.
Zdravilo Afoxolaner Merial bolhe ubije v osmih urah, klope pa v 48 urah.
The effectiveness of Afoxolaner Merial was investigated in both laboratory and field studies.
Učinkovitost zdravila Afoxolaner Merial so proučevali v laboratorijskih in terenskih študijah.
The company that makes NexGard has agreed that its scientific data can be used for Afoxolaner Merial (‘informed consent').
Podjetje, ki proizvaja zdravilo NexGard, se strinja, da se lahko znanstveni podatki o tem zdravilu uporabijo tudi za zdravilo Afoxolaner Merial („uporaba dokumentacije s soglasjem“).
For more information about using Afoxolaner Merial, see the package leaflet or contact your veterinarian or pharmacist.
Za več informacij glede uporabe zdravila Afoxolaner Merial glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
Afoxolaner Merial reduced the number of fleas and ticks by at least 98% and was at least as effective as a spot-on medicine containing pyriprole (another medicine against fleas and ticks).
Zdravilo Afoxolaner Merial je zmanjšalo število bolh in klopov za vsaj 98 % ter je bilo vsaj tako učinkovito kot zdravilo za kožni nanos, ki vsebuje piriprol (drugo zdravilo proti bolham in klopom).
This authorisation was based on the authorisation granted to NexGard in 2014 (‘informed consent').
Izdaja tega dovoljenja je temeljila na dovoljenju za promet z zdravilom NexGard, ki je bilo izdano leta 2014 (uporaba dokumentacije s soglasjem).
In an EU field study involving 146 dogs with flea and/or tick infestations, a single treatment with Afoxolaner Merial was effective in treating flea and tick infestations in dogs for up to 30 days after treatment.
V terenski študiji, ki so jo opravili v EU in v katero so vključili 146 psov z bolhami in/ali klopi, je bilo eno samo zdravljenje z zdravilom Afoxolaner Merial učinkovito proti bolham in klopom pri psih, kar je trajalo še do 30 dni po zdravljenju.
After being given, its actions last for at least 5 weeks against fleas and up to one month against ticks.
Po uporabi zdravilo proti bolham deluje najmanj pet tednov, proti klopom pa do enega meseca.
An overview of Afoxolaner Merial and why it is authorised in the EU
Pregled zdravila Afoxolaner Merial in zakaj je odobreno v EU
Afoxolaner Merial is available as chewable tablets in four different strengths for use in dogs of different weights.
Zdravilo Afoxolaner Merial je na voljo v obliki žvečljivih tablet v štirih različnih jakostih, namenjenih za uporabo pri psih z različno telesno maso.
Afoxolaner Merial reduced the number of live mites by 97% 56 days after starting treatment and by 98% 84 days after starting treatment.
Zdravilo Afoxolaner Merial je v 56 dneh po začetku zdravljenja zmanjšalo število živih garjavcev za 97%, 84 dni po začetku zdravljenja pa za 98%.
It blocks the normal movement of charged chloride particles (ions) in and out of nerve cells, especially those nerves that
Zavira normalno gibanje nabitih kloridnih delcev (ionov) v živčnih celicah in iz njih, zlasti tistih živcev, ki proizvajajo gama-aminomasleno kislino (GABA) za uravnavanje živčnega sistema.
Other information about Afoxolaner Merial
Druge informacije o zdravilu Afoxolaner Merial
Why is Afoxolaner Merial authorised in the EU?
Zakaj je zdravilo Afoxolaner Merial odobreno v EU?
Afoxolaner Merial is a veterinary medicine used to treat infestations with fleas and ticks, as well as demodectic and sarcoptic mange (skin infestations caused by two different types of mites) in dogs.
Afoxolaner Merial je zdravilo za uporabo v veterinarski medicini, ki je namenjeno zdravljenju infestacij z bolhami in klopi ter garjavosti vrste Demodex canis in Sarcoptes scabiei (kožne garjavosti, ki jo povzročata dve vrsti garjavcev) pri psih.
What is Afoxolaner Merial and what is it used for?
Kaj je zdravilo Afoxolaner Merial in za kaj se uporablja?
A second EU field study involved 31 dogs with demodectic mange which were treated monthly on 3 occasions with Afoxolaner Merial.
V drugo terensko študijo, opravljeno v EU, so vključili 31 psov z garjavostjo vrste Demodex canis, ki so jih trikrat zapored enkrat mesečno zdravili z zdravilom Afoxolaner Merial.
What are the risks associated with Afoxolaner Merial?
Kakšna tveganja so povezana z zdravilom Afoxolaner Merial?
Afoxolaner Merial reduced the number of live mites by 96% 28 days after starting treatment and by 100% 56 days after starting treatment.
Zdravilo Afoxolaner Merial je v 28 dneh po začetku zdravljenja zmanjšalo število živih garjavcev za 96%, 56 dni po začetku zdravljenja pa za
The active substance in Afoxolaner Merial, afoxolaner, acts as an ‘ectoparasiticide'.
Učinkovina v zdravilu Afoxolaner Merial, afoksolaner, deluje kot ektoparaziticid.
What benefits of Afoxolaner Merial have been shown in studies?
Kakšne koristi je zdravilo Afoxolaner Merial izkazalo v študijah?
A third EU field study involved 38 dogs with sarcoptic mange which were treated monthly for two months with Afoxolaner Merial.
V tretjo terensko študijo so vključili 38 psov z garjavostjo vrste Sarcoptes scabiei, ki so zdravilo Afoxolaner Merial prejeli enkrat na mesec dva meseca zapored.
Afoxolaner Merial contains the active substance afoxolaner.
Zdravilo Afoxolaner Merial vsebuje učinkovino afoksolaner.
How is Afoxolaner Merial used?
Kako se zdravilo Afoxolaner Merial uporablja?
How does Afoxolaner Merial work?
Kako zdravilo Afoxolaner Merial deluje?
List of the names, pharmaceutical form, strengths of the medicinal product, route of administration, applicants / marketing authorisation holder in the Member States
Seznam imen, farmacevtskih oblik, jakosti zdravil, poti uporabe zdravila, predlagateljev, imetnikov dovoljenja za promet z zdravilom v državah članicah
• Wash your hands
• Umijte si roke.
(picture 3)
(slika 3).
Date of first authorisation: 27 November 2001 Date of latest renewal: 06 October 2006
Datum prve odobritve: 27. november 2001 Datum zadnjega podaljšanja: 06. oktober 2006
If a drop misses the eye, try again.
Če kapljica zgreši oko, poskusite ponovno.
Now turn over
Obrnite stran
ATC code: S01E E04
Oznaka ATC: S01E E04
• If you use drops in both eyes, repeat the steps for the other eye
• Če uporabljate kapljice v obeh očesih, ponovite te korake tudi na drugem očesu.
A change in the colour of the skin around the eye may also occur.
Lahko se pojavi tudi sprememba barve kože okrog oči.
Don't put in any more drops until it's time for the next regular dose.
Kapljic ne vkapajte ponovno, dokler ne bo čas za naslednji redni odmerek.